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Abstract We have recently cloned a putative chemoattractant
receptor, named CRTH2, which is preferentially expressed on
human T-helper- (Th) 2 but not Th1 cells. In this study, we
demonstrated that CRTH2 is also highly expressed on peripheral
blood basophils and eosinophils. Our search for a CRTH2 ligand
identified mast cells as the possible producers of a ligand. When
stimulated with an anti-FcOR1 antibody, cord blood-derived mast
cells secreted factor(s) that induced Ca2+ mobilization in
CRTH2-expressing K562 cells but not in mock transfected cells.
These findings implied the involvement of CRTH2 in mast cell-
mediated immune responses such as allergic reactions.
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1. Introduction
Interactions of receptors on leukocytes with chemoattrac-
tants play an important role in tissue- or site-speci¢c recruit-
ment of leukocytes under various physiological and patholog-
ical conditions [1^3]. A complete understanding of this
process might allow the development of new therapies for
in£ammatory and allergic disorders [4]. We have recently
cloned a new chemoattractant receptor-like molecule, named
CRTH2, from a human Th2 clone [5]. Notwithstanding the
paucity of information on the corresponding ligand(s),
CRTH2 is intriguing in that it is preferentially expressed on
Th2- but not Th1-type cells among peripheral blood CD4 T-
lymphocytes [5]. The highest homology in the amino acid
sequence is found with members of the N-formyl peptide re-
ceptor subfamily such as FMLP receptor but the similarity
seems to be insu⁄cient to classify CRTH2 as the members
of the subfamily [5]. These ¢ndings suggest that CRTH2 uti-
lizes an unknown ligand and thereby confers a particular
property in the behavior and function of Th2 cells in vivo
[6^8]. In this study, we examined the expression of CRTH2
in the entire population of leukocytes in order to understand
the role of CRTH2 in the immune system. Our results dem-
onstrated that CRTH2 is highly expressed on basophils and
eosinophils, both of which, as well as Th2 cells, are known to
be important in allergic diseases. Furthermore, we found that
culture supernatants of mast cells treated with anti-high-a⁄n-
ity IgE receptor (FcOR1) antibody contain an agonist(s) for
CRTH2 in a Ca2 mobilization assay.
2. Materials and methods
2.1. Cells
Peripheral blood mononuclear cells (PBMCs) and granulocytes
were isolated from heparinized peripheral blood of consented healthy
subjects by density gradient centrifugation on a metrizoate-based sup-
porting medium, Mono-Poly Resolving medium (Dainippon Pharma-
ceutical, Osaka, Japan). Mast cells were obtained by culturing CD34
cord blood mononuclear cells (CBMCs) for 12^18 weeks in the pres-
ence of recombinant human stem cell factor (R and D Systems, Min-
neapolis, MN, USA) and interleukin (IL)-6 (Intergen, Purchase, NY,
USA), as described previously [9]. To facilitate mast cell maturation,
recombinant human IL-4 (10 ng/ml, Genzyme, Cambridge, MA,
USA) and human IgE (1 Wg/ml, Cosmo Bio, Tokyo, Japan) were
added to the cultures during the last 2^3 weeks before harvesting
[10,11]. The purity of mast cells in the cultures was usually s 60%
as assessed by staining with alcian blue or an anti-FcOR1 mAb CRA1
(Kyokuto Pharmaceutical, Ibaraki, Japan) [12] and by expression of
tryptase which was measured by £ow cytometry as reported [12].
CRTH2-transfected line K562/B19 and its control line K562/neo
were generated by stable introduction into K562 cells of the
CRTH2-expression plasmid pRc/B19 [5] and its control plasmid
pRc/CMV (Invitrogen, San Diego, CA, USA), respectively, and by
selection with geneticin (400 Wg base/ml, Sigma Chemical, St. Louis,
MO, USA). K562/B19 cells expressing high level CRTH2 were se-
lected by sorting with anti-CRTH2 mAb BM16 as described [5] (see
Fig. 3A).
2.2. Antibodies and £ow cytometry
Biotinylated BM16 (rat anti-CRTH2) and control rat IgG2a were
described previously [5]. A CRTH2-speci¢c rat mAb BM7 (IgG2a),
which was derived from the same fusion experiment as BM16 [5], was
selected and used for its antagonistic activity in this study. BM7 and
BM16 compete with each other for binding to CRTH2-expressing
cells. For £ow cytometric analysis, CRA1 was labeled with £uorescein
isothiocyanate (FITC) (Molecular Probes, Eugene, OR, USA). The
following materials were obtained from Becton Dickinson (San Jose,
CA, USA): FITC-conjugated mAbs to CD3 (clone Leu-4), CD4 (Leu-
3a), CD8 (Leu-2a), CD14 (Leu-M3), CD19 (Leu-12) and HLA-DR
(L243); phycoerythrin (PE)-labeled mAbs to CD4, CD8 and CD56
(Leu-19); allophycocyanin (APC)-coupled mAbs to CD3, CD4, CD14
and CD19; and appropriate isotype-matched controls. FITC-conju-
gated mAbs to CD9 (M-L13), CD16 (3G8) and CD33 (HIM3-4), and
RED670-labeled streptavidin were purchased from PharMingen (San
Diego, CA, USA) and GIBCO BRL (Long Island, NY, USA). For
multiple staining, cells were ¢rst pre-incubated at room temperature
for 30 min in washing bu¡er [0.5% bovine serum albumin (BSA)/2 mM
EDTA/0.05% NaN3/PBS, pH 7.3] containing 10% normal rat serum,
then biotinylated BM16 or control rat IgG2a (¢nal 10 Wg/ml) was
added to the cells along with labeled mAbs to surface markers. The
cells were incubated at 4‡C for 30 min, washed with the washing
bu¡er and incubated with RED670-labeled streptavidin at 4‡C
for 30 min in the washing bu¡er. Stained cells were analyzed on a
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FACSCalibur £ow cytometer using CellQuest software (Becton Dick-
inson).
2.3. Reverse transcription (RT)-PCR analysis
Basophils were puri¢ed to homogeneity (s 97% pure as determined
by May-Gru«nwald Giemsa staining) from pooled PBMCs of healthy
volunteers by negative selection using mAbs to CD3, CD4, CD8,
CD14, CD19 and CD56, and anti-mouse IgG-coated magnetic beads
(Miltenyi Biotec, Bergisch Gladback, Germany), followed by positive
selection using anti-FcOR1 mAb CRA1 and the magnet beads [13^15].
Eosinophils (s 99% pure) were similarly obtained from pooled gran-
ulocytes by negative selection with mAbs to CD3, CD4, CD8, CD14,
CD16, CD19, CD56 and FcOR1, followed by positive selection with
anti-CD9 [15,16]. RT-PCR was performed as described previously [5]
except for primers for CRTH2 which were 5P-AATCCTGTG-
CTCCCTCTGTGCCCA (sense) and 5P-GGGAAGCAGAGGCCAA-
CAGGTCG (antisense).
2.4. Ca2+ mobilization assay
Cells were loaded with 5 WM Fura-2AM (Dojindo, Kumamoto,
Japan) at 37‡C for 1 h in RPMI 1640 medium supplemented with
10% fetal bovine serum, washed with Hanks’ balanced salt solution
(HBSS), then resuspended in HBSS containing 0.1% BSA and 10 mM
Fig. 1. Expression of CRTH2 on normal blood leukocytes. Whole leukocytes (PBMCs+granulocytes) from a representative healthy adult were
stained with the indicated antibodies as described in Section 2. Staining patterns with control antibodies are shown in panels c, g, j, i and o.
Percentages of positive or negative cells in each gated region are presented in each panel. Arrows in panels p^r indicate basophils.
Fig. 2. Preferential expression of CRTH2 mRNA in basophils, eosi-
nophils and Th2 cells. Total RNAs (0.4 Wg) from the indicated cells
were analyzed for relative levels of CRTH2 mRNA by RT-PCR as
described previously [5]. The amounts of RT reaction product sub-
jected to PCR are indicated. Th1 and Th2 clones used in this analy-
sis were MID3 and 6L21, respectively [5]. DNA was stained with
ethidium bromide.
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HEPES (pH 7.3) at 106 cells/ml. Cells were transferred into quartz
cuvettes (400 Wl) that were placed in a £uorospectrometer LS50B
(Perkin-Elmer, Norwalk, CT, USA). The test stimulant (10 Wl) was
then added to the cuvettes at indicated time points. The ratio of
£uorescence intensities (emission wavelength, 510 nm) at excitation
wavelengths 340 nm and 380 nm were calculated using FL-Winlab
software (Perkin Elmer) as reported [17].
3. Results and discussion
We ¢rst sorted CRTH2-expressing cells from whole periph-
eral blood leukocytes (PBMCs+granulocytes) by using anti-
CRTH2 mAb BM16, as described previously [5], then charac-
terized CRTH2 positive cells microscopically. The May-Gru«n-
wald Giemsa staining illustrated that basophils and eosino-
phils were greatly enriched by the sorting. The combined
percentages of these two cell types rose from 6 5% of un-
sorted whole leukocytes to s 60% of BM16-sorted leukocytes
with several normal adults. These results suggested that, in
addition to Th2-type T-cells, basophils and eosinophils highly
expressed CRTH2.
Fig. 3. Ca2 mobilization in K562/B19 cells. A: Expression levels of CRTH2 on K562/neo and K562/B19 cells. Cells indicated at the top of
each panel were stained with biotinylated BM16 (solid line) or control IgG2a (dotted line) as described in Section 2. B: Ca2 mobilization as-
say. Cell suspensions of Fura-2-loaded test cells were either directly subjected to Ca2 mobilization assay (experiments a^g) or treated with the
indicated antibody (¢nal 300 Wg/ml) at room temperature for 20^30 min, then subjected to the assay (experiments h^k). Arrows indicate the
time of stimulant (sample) addition. Fluorescence ratios induced by the addition of ionomycin (¢nal 2 WM) or Triton X-100 (¢nal 0.4%, Sigma)
were 2.5^4.6 or 7.2^10.5, respectively.
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To examine in detail the expression level of CRTH2 on
whole blood leukocytes, a six-parameter £ow cytometric anal-
ysis was performed with whole leukocytes from ¢ve healthy
adults. All donors showed a similar pattern of CRTH2 ex-
pression, which was seen in at least four di¡erent cell types.
Results from a representative donor are shown in Fig. 1.
Among granulocytes, which were de¢ned by signals in for-
ward and side light scatter, and surface phenotypes (negative
for lymphocyte/monocyte lineage markers CD3, CD4, CD8,
CD14, CD19 and CD56), CRTH2 was preferentially ex-
pressed on CD163 leukocytes, which correspond to eosino-
phils (Fig. 1, region (R) 1 and R2, panels a^d) [15,16]. In the
region containing mostly lymphocytes with some monocytes,
a high expression of CRTH2 was typically observed on leu-
kocytes with CD33, CD43, CD83, CD143, CD193, CD563
and FcOR1bright phenotypes, which are considered to be baso-
phils (Fig. 1, R3 and R4, panels e^h) [13^15]. In the same
region, a small portion of CD3 T-cells expressed various
levels of CRTH2 as reported earlier [5] (Fig. 1, R3 and R6,
panels i and l^n), most of which, including CD8 T-cells,
showed the Th2-type cytokine pattern in separate experiments
(data not shown). In addition, the same region contained cells
that weakly expressed CRTH2 with phenotypes of CD33,
CD4weak, CD143 to intermediate, CD193, and CD563 (Fig. 1,
R3 and R7, panels i and o^r). These leukocytes also expressed
CD33, HLA-DR and often CD16 (data not shown), suggest-
ing they consisted of monocytes [18] and/or dendritic cells
[19]. Further studies are necessary to fully characterize these
leukocytes. In this study, CRTH2 expression was not identi-
¢ed in other leukocyte populations including NK cells (CD33/
CD56) and B-cells (CD19) (Fig. 1 panels k and p, respec-
tively).
The preferential expression of CRTH2 in basophils and
eosinophils as well as Th2 cells was further con¢rmed by
the expression of CRTH2 mRNA, which was examined by
RT-PCR analysis using highly puri¢ed cell populations (Fig.
2). However, the question whether all of basophils and eosi-
nophils in blood express CRTH2 remains to be solved.
The ¢nding that CRTH2 is commonly expressed by baso-
phils, eosinophils and Th2 cells indicated the possible produc-
tion of a physiological ligand for CRTH2 at the sites of aller-
gic in£ammation since all three cell types are known to
selectively accumulate in such sites [20^22]. Mast cells also
reside at these sites and play a central role in allergic in£am-
matory process through the release of various mediators
[23,24]. Thus, in the next step we examined whether mast cells
produce a CRTH2 ligand. Since it was di⁄cult to obtain a
su⁄cient number of pure mast cells from human tissues, we
generated such cells in vitro from CD34 CBMCs. The cells
were incubated at 2U105 cells/ml in the presence or absence
of an anti-FcOR1 mAb CRA1 (1 Wg/ml) at 37‡C for 5^6 h,
then the agonist activity in the culture supernatants was meas-
ured by a Ca2 mobilization assay using Fura-2-loaded K562/
B19 cells (Fig. 3A). As shown in Fig. 3B, a weak agonist
activity was detected in supernatants from unstimulated
mast cell cultures (panel b). Marked enhancement of the ago-
nist activity was seen with cells stimulated with CRA1 (CRA1
supernatants), while control IgG (10 Wg/ml) did not induce
any enhancement and CRA1 itself was not active in the assay
(Fig. 3B, panels a, c and d). These results indicated that the
agonist activity was derived from FcOR1 cells, namely, mast
cells, but not from other cell types in the cultures. The same
CRA1 supernatants elicited no Ca2 mobilization in K562/
neo cells (Fig. 3B, panel e) not even in K562/B19 cells when
they were pre-treated with an antagonistic anti-CRTH2 mAb
BM7 (Fig. 3B, panels h^k), indicating that both spontane-
ously released and CRA1-induced agonist activities were
mediated by CRTH2. In addition to mast cells, blood leuko-
cytes produce various types of chemoattractants including cy-
tokines and chemokines [24]. However, no signi¢cant
CRTH2-speci¢c agonist activity was detected in culture super-
natants of PBMCs, granulocytes and IL-2-maintained T cells,
each of which was treated with various combinations of stim-
uli ; phorbol myristate acetate (PMA, 20 ng/ml, Sigma), ion-
omycin (0.5 WM, Sigma) and phytohemagglutinin (PHA, 5 Wg/
ml, Sigma) (Fig. 3B, panels f and g and data not shown).
These results suggested that the natural ligand for CRTH2
is produced by restricted cell types including mast cells.
The above results demonstrated that CRTH2 is commonly
expressed on three cell types (basophils, eosinophils and Th2-
type T-cells) involved in allergic processes. Interestingly, the
chemokine receptor shared by these three cell types is CCR3,
a receptor for CC-chemokines, eotaxin, eotaxin 2, RANTES,
MCP-2, -3 and -4, [8,25]. Our previous study showed, how-
ever, that CRTH2 does not respond to either eotaxin or
RANTES [5], and the present study indicates that CRTH2
interacts with a mast cell-derived factor, which, from a series
of preliminary experiments, has a molecular mass of 6 5 kDa
(Hirai, H., unpublished data). Although extensive studies are
required to characterize the ligand, our results presented here
suggest that CRTH2 mediates the recruitment and/or activa-
tion of these three cell types at sites containing mast cells
activated by invading allergens.
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